Mersana Therapeutics (MRSN) Competitors $6.60 -0.25 (-3.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.60 0.00 (0.00%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRSN vs. NKTX, KRRO, CTNM, IMRX, THTX, ACTU, FATE, CLLS, LXEO, and CGENShould you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Nkarta (NKTX), Korro Bio (KRRO), Contineum Therapeutics (CTNM), Immuneering (IMRX), Theratechnologies (THTX), Actuate Therapeutics (ACTU), Fate Therapeutics (FATE), Cellectis (CLLS), Lexeo Therapeutics (LXEO), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry. Mersana Therapeutics vs. Its Competitors Nkarta Korro Bio Contineum Therapeutics Immuneering Theratechnologies Actuate Therapeutics Fate Therapeutics Cellectis Lexeo Therapeutics Compugen Mersana Therapeutics (NASDAQ:MRSN) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation. Which has more volatility and risk, MRSN or NKTX? Mersana Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Which has better valuation and earnings, MRSN or NKTX? Mersana Therapeutics has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$40.50M0.81-$69.19M-$14.75-0.45NkartaN/AN/A-$108.79M-$1.51-1.40 Is MRSN or NKTX more profitable? Nkarta has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -217.63%. Nkarta's return on equity of -26.64% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-217.63% -990.16% -48.87% Nkarta N/A -26.64%-21.62% Do analysts prefer MRSN or NKTX? Mersana Therapeutics presently has a consensus target price of $130.00, suggesting a potential upside of 1,869.70%. Nkarta has a consensus target price of $14.33, suggesting a potential upside of 576.10%. Given Mersana Therapeutics' higher possible upside, equities research analysts plainly believe Mersana Therapeutics is more favorable than Nkarta.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Do institutionals & insiders hold more shares of MRSN or NKTX? 93.9% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 13.0% of Mersana Therapeutics shares are owned by insiders. Comparatively, 8.4% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to MRSN or NKTX? In the previous week, Mersana Therapeutics and Mersana Therapeutics both had 3 articles in the media. Nkarta's average media sentiment score of 1.15 beat Mersana Therapeutics' score of 0.00 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mersana Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nkarta 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMersana Therapeutics and Nkarta tied by winning 7 of the 14 factors compared between the two stocks. Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRSN vs. The Competition Export to ExcelMetricMersana TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.15M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-0.4517.6228.6723.80Price / Sales0.81179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book-3.448.508.275.55Net Income-$69.19M-$55.06M$3.24B$259.03M7 Day PerformanceN/A-3.98%-3.69%-4.59%1 Month Performance-5.61%9.59%4.33%4.46%1 Year Performance-83.60%6.72%25.95%18.03% Mersana Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRSNMersana Therapeutics4.0345 of 5 stars$6.60-3.6%$130.00+1,869.7%-85.3%$34.15M$40.50M-0.45150Analyst DowngradeStock SplitGap DownNKTXNkarta2.416 of 5 stars$2.20+1.9%$14.33+551.5%-66.9%$153.27MN/A0.00140News CoverageKRROKorro Bio1.3162 of 5 stars$15.61-2.5%$102.43+556.2%-68.2%$150.34M$2.27M0.0070CTNMContineum Therapeutics2.5052 of 5 stars$5.51-4.5%$22.50+308.3%-69.4%$149.28M$50M0.0031News CoveragePositive NewsIMRXImmuneering2.9174 of 5 stars$3.91-3.7%$13.25+238.9%+149.6%$146.10M$320K0.0060Upcoming EarningsGap DownTHTXTheratechnologiesN/A$3.16-0.3%N/A+124.1%$145.76M$85.87M0.00140Positive NewsACTUActuate Therapeutics2.0053 of 5 stars$6.86-5.5%$20.50+198.8%N/A$142.44MN/A0.0010News CoverageFATEFate Therapeutics3.9736 of 5 stars$1.30+4.8%$3.83+194.9%-78.1%$142.11M$13.63M0.00550Positive NewsAnalyst UpgradeCLLSCellectis2.574 of 5 stars$2.85+13.1%$4.00+40.4%+36.6%$140.07M$49.22M0.00290Upcoming EarningsGap UpHigh Trading VolumeLXEOLexeo Therapeutics2.3826 of 5 stars$4.26+3.1%$16.60+289.7%-64.7%$137.10M$650K0.0058News CoverageAnalyst ForecastGap DownCGENCompugen2.0068 of 5 stars$1.51-1.3%$4.00+164.9%-18.7%$136.53M$27.86M-9.4470Upcoming Earnings Related Companies and Tools Related Companies NKTX Competitors KRRO Competitors CTNM Competitors IMRX Competitors THTX Competitors ACTU Competitors FATE Competitors CLLS Competitors LXEO Competitors CGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRSN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
